-
Finerenone plus SGLT2 inhibitor reduces albuminuria more than either drug alone
06 Jun 2025 18:02 GMT
… and empagliflozin than with either drug alone, according to study … “[The combination] is safe, and drug discontinuation due to hypotension, acute … support from Akebia Therapeutics, Alnylam, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Chinook, …
-
U.S. Orphan Designated Drugs Market Research Report 2025: $190 Billion Opportunities, Drugs Sales, Price, Dosage & Clinical Trials Insights to 2030 - ResearchAndMarkets.com
19 May 2025 18:48 GMT
… associated with orphan drug development can be significant.
More drugs have over … years acquired orphan drug status. To date, hundreds of drugs in development …
10.8 AstraZeneca
10.9 Bayer HealthCare
10.10 BioMarin Pharmaceutical
10 …
-
Rx Rundown: Merck, Gilead Sciences, Apogee Therapeutics and more
11 Jul 2025 13:49 GMT
… FDA acceptance of new drug application for ET-600 … ’s endometriosis-related pain drug is being discontinued after … response to a challenge from Bayer Healthcare, BBB National Programs’ National … reported that its experimental drug reduced the symptoms of …
-
Liver Fluke Treatment Market Growth Drivers, Industry Trends And Forecasts 2025-2034 | Global Liver Fluke Treatment Market Grows At 4.8% CAGR Amid Rising Anthelmintic Drug Demand
14 Apr 2025 12:59 GMT
… pharmaceutical formulations, including controlled drug release mechanisms and improved bioavailability … to commonly used anthelmintic drugs
3.3 Growth potential … 10 Company Profiles AdvaCare Pharma Bayer Healthcare GlaxoSmithKline Lupin Pharma Merck …
-
Vaccination Added to Pillars of Heart Disease Prevention
08 Jul 2025 11:18 GMT
… prevention besides antihypertensives, lipid-lowering drugs, and medications that treat diabetes … relationships with Abbott, Amgen, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Cytokinetics, Daiichi Sankyo …
-
Implantable Drug Delivery Devices Market Generated Opportunities, Future Scope | Boston Scientific Corporation
23 Dec 2024 15:35 GMT
Implantable drug delivery devices are used to administer drugs and fluids without the … & Lomb Inc.
• Allergan Inc.
• Bayer Healthcare
• Alimera Sciences
• Eyepoint Pharmaceuticals
• DSM …
-
Popular diabetes and obesity drugs also protect kidneys, study shows
26 Nov 2024 00:00 GMT
COI Statement
SVB reports consulting fees from Bayer, AstraZeneca, GSK, and Vifor Pharma; speaking fees from Bayer, AstraZeneca, Pfizer, and Vifor Pharma (all honoraria paid to his institution); and non-financial research support from Bayer. MMYL reports …
-
Marksans Pharma gets USFDA nod for generic allergy drug
22 Nov 2024 08:04 GMT
… the U.S. Food and Drug Administration (USFDA) for its Abbreviated … New Drug Application (ANDA) for Loratadine Tablets … .
The approved drug is a generic version of Bayer Healthcare’s Claritin tablets …
-
U.S. FDA Accepts Supplemental New Drug Application for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
21 Nov 2024 12:16 GMT
… and drug-induced liver injury.
Drug Interactions
Effect of Other Drugs on …
Effects of NUBEQA on Other Drugs – NUBEQA inhibits breast cancer … (darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2023.
Hyuna …
-
Implantable Drug Delivery Devices Global Market 2024 To Reach $28.91 Billion By 2028 At Rate Of 8.1%
30 Oct 2024 12:00 GMT
… the implantable drug delivery devices market include AbbVie Inc., Bayer HealthCare, Medtronic Inc … 47;report/drug-screening-global-market-report
Drugs For Hormonal Replacement … .com/report/drugs-for-hormonal-replacement-therapy-global …
About
© 1995-2025